Based on our previous findings, in this study, we compared dacomitinib and afatinib in terms of efficacy, safety, progression patterns, and resistance mechanisms in patients with NSCLC carrying uncommon EGFR mutations with the aim of obtaining valuable evidence for clinical decision making. Here, EGFR is linked to non-small cell lung carcinoma.